Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DC7JQ8
|
|||
| Drug Name |
Omilancor
|
|||
| Synonyms |
BT-11; 1912399-75-7; A4Y49H6YY8; CHEMBL4788758; Piperazine-1,4-diylbis((6-(1H-benzo[d]imidazol-2-yl)pyridin-2-yl)methanone); Methanone, 1,1'-(1,4-piperazinediyl)bis(1-(6-(1H-benzimidazol-2-yl)-2-pyridinyl)-; [4-[6-(1H-benzimidazol-2-yl)pyridine-2-carbonyl]piperazin-1-yl]-[6-(1H-benzimidazol-2-yl)pyridin-2-yl]methanone; OMILANCOR; BT-11; Omilancor; OMILANCOR [INN]; UNII-A4Y49H6YY8; BT11; SCHEMBL17706588; GTPL10363; BCP32788; BT 11; BT11; Example 1 [US9556146B2]; BDBM50558735; s6419; AKOS037515592; CS-7521; SB18706; HY-102013
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Ulcerative colitis [ICD-11: DD71; ICD-9: 556] | Phase 2 | [1] | |
| Company |
Landos Biopharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C30H24N8O2
|
|||
| Canonical SMILES |
C1CN(CCN1C(=O)C2=CC=CC(=N2)C3=NC4=CC=CC=C4N3)C(=O)C5=CC=CC(=N5)C6=NC7=CC=CC=C7N6
|
|||
| InChI |
InChI=1S/C30H24N8O2/c39-29(25-13-5-11-23(31-25)27-33-19-7-1-2-8-20(19)34-27)37-15-17-38(18-16-37)30(40)26-14-6-12-24(32-26)28-35-21-9-3-4-10-22(21)36-28/h1-14H,15-18H2,(H,33,34)(H,35,36)
|
|||
| InChIKey |
MVHWZNBAQIGPOQ-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | LanC-like protein 2 (LANCL2) | Target Info | Agonist | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05057273) A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Oral BT-11 in Crohn's Disease Patients With Moderate to Severe Disease. U.S.National Institutes of Health. | |||
| REF 2 | Correction to: Efficacy, Safety, and Tolerability of ?Omilancor in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Ulcerative Colitis. Inflamm Bowel Dis. 2022 Dec 1;28(12):1938. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.